Loading the latest PSX data…
Loading the latest PSX data…
Abbott Laboratories (Pakistan) LimitedShariah-compliantKSE-100
+3.93 (+0.39%) today
Market closed, last update Nov 16, 2026 10:37 PMThe Abbott Laboratories (Pakistan) share price was Rs 1,003.93 (+0.39%) at the last PSX update (Nov 16, 2026 10:37 PM). ABOT is a pharmaceuticals stock in the KSE-100 index with a market value of Rs 98.3bn.
Last session's range16 Nov 2026
997.5026% up the range1,022.00
52-week range
821.0040% up the range1,274.00
Price limits (circuit breakers)
900.0052% up the range1,100.00
ABOT ranks better than 80% of the 309 liquid PSX stocks we score. Each factor is a 0-100 rank (value is ranked half within pharmaceuticals). Education only, not a buy or sell signal.
+12.5% over 6M(KSE-100 +4.9%)
Daily bars from PSX's end-of-day market summary. Prices before a bonus issue, right issue or split are adjusted so the chart stays continuous; cash dividends are not taken out.
Full-screen ABOT chart with levelsDownload ABOT price history (CSV)Compare ABOT with GLAXO
From daily closes to 2026-11-16. A description of the trend, not a forecast.
Trend reading
Uptrend
Down5 up · 0 down signalsUp
| S2 | S1 | Pivot | R1 | R2 |
|---|---|---|---|---|
| 983.31 | 993.62 | 1,007.81 | 1,018.12 | 1,032.31 |
+31.7% over 5 years
Monthly closing prices from the PSX Data Portal, since 2000. Earlier prices are adjusted for 5 bonus issues and splits (2001–2006; one share then is about 2.4 shares now) so the line shows the value of one original share.
| Announced | Period | Payout | Profit after tax | EPS (Rs) | Books close |
|---|---|---|---|---|---|
| 27 Oct 15:19 | 9 months to 30 Sept | None | Rs 6,684.2m | 68.28 | – |
| 28 Aug 16:29 | Half year to 30 Jun | None | Rs 4,140.2m | 42.29 | – |
| 28 Apr 11:42 | 1st quarter to 31 Mar | None | Rs 1,940.3m | 19.82 | – |
Measured from October 2021 to October 2026 using PSX daily closes.
For comparison, the KSE-100 (which includes reinvested dividends) returned about 30.5% a year over the same five years, an unusually strong period. Past returns do not predict future ones.
| Measure | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Sales growth | +10.6% | +22.9% | +12.6% | – |
| Profit growth | +52.2% | +1,899.5% | −91.3% | – |
| EPS growth | +52.2% | +1,902.2% | −91.3% | – |
| Net margin | 10.6% | 7.7% | 0.5% | 6.1% |
| Measure | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|---|
| Sales growth | +4.1% | – | – | – |
| Profit growth | +39.6% | – | – | – |
| EPS growth | +39.6% | – | – | – |
| Net margin | 12.3% | 10.8% | 11.0% | 9.2% |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Sales | Rs 75.4bn | Rs 68.2bn | Rs 55.5bn | Rs 49.3bn |
| Profit after tax | Rs 8.0bn | Rs 5.2bn | Rs 262m | Rs 3.0bn |
| Earnings per share (Rs) | 81.37 | 53.46 | 2.67 | 30.69 |
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|---|
| Sales | Rs 20.6bn | Rs 20.3bn | Rs 17.7bn | Rs 19.8bn |
| Profit after tax | Rs 2.5bn | Rs 2.2bn | Rs 1.9bn | Rs 1.8bn |
| Earnings per share (Rs) | 25.99 | 22.47 | 19.82 | 18.62 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Gross margin | 35.1% | 29.0% | 21.4% | 29.5% |
| Net margin | 10.6% | 7.7% | 0.5% | 6.1% |
| EPS growth | 52.2% | 1,902.3% | -91.3% | -49.7% |
| PEG | 0.25 | 0.01 | -1.89 | -0.30 |
Rupee amounts from PSX filings (thousands converted to Rs m/bn). Data by Capital Stake via the PSX Data Portal; standardised, so it can differ from the annual report. Latest quarter (Q3 2026) EPS rose 39.6% from the same quarter a year earlier.
| Measure | ABOT | Sector median | Reading |
|---|---|---|---|
| P/E | 10.6 | 12.4 | Cheaper than peers |
| Dividend yield | 4.4% | 5.2% | Below peers |
| Net margin | 10.6% | 8.8% | Above peers |
| EPS growth | +52.2% | +28.2% | Above peers |
| 1-year return | −8.1% | −14.7% | Above peers |
Sector P/E check. At the sector's median P/E of 12.4, last year's EPS of Rs 81.37 would price ABOT at about Rs 1,005.53 (+0% from today). A rough yardstick only: sectors hold very different businesses, and the market prices future profits, not last year's.
Estimate a fair value for ABOT (Graham, Lynch, DCF)ABOT pivot levels
Ratios as published on the PSX Data Portal (standardised by Capital Stake), latest financial year on the right.
Work out your ABOT dividend income after tax
PSX quotes payouts as a percentage of face value; cash per share assumes the usual Rs 10 face value. You get the dividend if you own the shares before the books close.
Market value
2nd of 18
Rs 98.3bn
P/E (cheapest first)
3rd of 13
10.6
Dividend yield
5th of 7
4.4%
1-year return
4th of 15
-8.1%
EPS growth
6th of 15
52.2%
Net margin
7th of 16
10.6%
danioPSX score
2nd of 13
80/100
| GLAXOGlaxoSmithKline Pakistan Limited | Rs 108.1bn | +0.96% | 9.8 | 6.1% | −13.9% | 89 |
| ABOTThis stock · Abbott Laboratories (Pakistan) Limited | Rs 98.3bn | +0.39% | 10.6 | 4.4% | −8.1% | 80 |
| HALEONHaleon Pakistan Limited | Rs 80.7bn | −1.06% | 12.4 | 3.6% | −15.7% | 65 |
| HINOONHighnoon Laboratories Limited | Rs 50.7bn | −0.30% | 12.3 | 5.4% | −15.4% | 78 |
| SEARLThe Searle Company Limited | Rs 46.7bn | +0.27% | 12.0 | – | −22.9% | 53 |
| AGPAGP Limited | Rs 43.5bn | −0.59% | 24.3 | 5.1% | −16.6% | 50 |
| HPLHoechst Pakistan Limited | Rs 38.5bn | +0.14% | 11.0 | 6.9% | −2.5% | – |
| FEROZFerozsons Laboratories Limited | Rs 15.9bn | +0.67% | 23.1 | 1.6% | −8.8% | 39 |
| CPHLCiti Pharma Ltd. | Rs 14.5bn | +0.19% | 17.8 | – | −21.6% | 31 |
| GSKCHGlaxoSmithKline Consumer Healthcare | Rs 14.1bn | −3.13% | – | – | – | – |
| BFBIOBF Biosciences Limited | Rs 12.0bn | +0.64% | 18.3 | – | −10.1% | 44 |
| MACTERMacter International Limited | Rs 11.8bn | −1.58% | 3.7 | – | −28.2% | 51 |
| SAPLSanofi-Aventis Pakistan Limited | Rs 8.4bn | 0.00% | – | – | – | – |
| OTSUOtsuka Pakistan Limited | Rs 5.7bn | +5.78% | 11.6 | – | +35.9% | 65 |
| LIVENLiven Pharma Limited | Rs 4.9bn | +10.00% | – | – | −9.0% | 11 |
Swipe the table sideways for more columns.
No director or substantial-shareholder trades in ABOT read from PSX notices yet.
Read automatically (OCR) from the disclosure images companies file with PSX under Regulation 5.6.1(d). A digit can be misread, so check the original notice before relying on a figure. Value = shares × price. Not investment advice. All PSX insider trades
Abbott Laboratories (Pakistan) Limited is a public limited company incorporated in Pakistan on July 02, 1948. The Company is principally engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products.
Where the price sits in its 52-week range
Low 821.0040% of the way upHigh 1,274.00
Data: PSX Data Portal (Nov 16, 2026 10:37 PM); company data refreshed 16 Nov; daily bars from PSX market summaries; five-year record from danioPSX research. Logos are trademarks of their owners. Not a recommendation to buy or sell ABOT. Official PSX page for ABOT